Mumbai, January 29 (UITV) – Country’s leading pharma company Cipla on Tuesday reported a 49 per cent increase in its consolidated net profit for the third quarter of FY 2025. The company’s net profit increased to Rs 1,574.6 crore from Rs 1,068.5 crore in the same quarter of the previous year (Q2 FY 2025). This increase is a result of the company’s strong performance and effective strategies.
The company said in its exchange filing that its revenue from operations grew 7 per cent to Rs 7,073 crore as against Rs 6,604 crore in the third quarter of FY 2024. However, it remained almost stable on a quarter-on-quarter basis, as the revenue stood at Rs 7,051 crore in the second quarter of FY 2025.
Revenue from the company’s business in India grew 10 per cent year-on-year to Rs 3,146 crore. Its branded prescription business outpaced market growth in key treatments. Cipla said its products gained greater market share in India, driving its growth.
Cipla’s EBITDA (profit before interest, tax, depreciation and amortisation) grew 15.7 per cent year-on-year to Rs 1,989 crore, while EBITDA margin expanded 184 basis points to 28.1 per cent. The company said its sustained margins were a result of improved operational efficiency and an intensive market-focused strategy. This meant that the company effectively controlled its costs and operated more profitably.
Although Cipla’s expenses for the quarter grew 5 per cent year-on-year to Rs 5,378 crore, these expenses were 1.3 per cent lower on a quarter-on-quarter basis. This shows that the company adopted various measures to keep expenses in check.
Cipla’s new enterprise segment also performed well, earning revenue of Rs 341 crore in the third quarter of FY 2025. This income is higher than the income of Rs 281 crore in the same period of FY 2024 and the income of Rs 320 crore in the previous quarter. This increase was due to Cipla’s expansion into new products and markets. The company said that the company’s growth has been boosted due to strong performance in emerging markets and Europe.
In addition, Cipla also said that its trade generic segment is now back on the path of growth and its consumer health brand continues to expand. This shows that the company has expanded its product portfolio and achieved success in new segments.
After the company’s financial results, Cipla’s stock also saw a rise. Cipla’s stock closed at Rs 1,427 with a gain of Rs 30.9. This growth is a symbol of investor confidence and the stable financial performance of the company.
Cipla’s performance reflects the demand for its products not only in India but also internationally. The company’s success has been possible due to its continuous innovation, improved operations and strategic expansion. In the coming time, Cipla is set to expand further in its global markets and launch new products, which will further strengthen its predictability and growth trajectory.
This financial performance of Cipla makes it clear that the company is achieving success in its strategies and is emerging as a strong player in the pharmaceutical industry.